Information Journal Paper
APA:
Copy. (2017). Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 35(-), 0-0. SID. https://sid.ir/paper/746570/en
Vancouver:
Copy. Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY[Internet]. 2017;35(-):0-0. Available from: https://sid.ir/paper/746570/en
IEEE:
Copy, “Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC),” JOURNAL OF CLINICAL ONCOLOGY, vol. 35, no. -, pp. 0–0, 2017, [Online]. Available: https://sid.ir/paper/746570/en